Drug Profile
Ozanezumab - GlaxoSmithKline
Alternative Names: 1223249; GSK1223249Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Monoclonal antibodies
- Mechanism of Action Nogo protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis
Most Recent Events
- 01 Jan 2015 GlaxoSmithKline completed a phase II trial in Amyotrophic lateral sclerosis in USA, Australia, Belgium, Canada, France, Germany, Italy, Japan, South Korea and Netherlands and United Kingdom (NCT01753076)
- 13 Feb 2014 GlaxoSmithKline completes enrolment in its phase II trial for Amyotrophic lateral sclerosis in USA, Canada, European Union, Australia, Japan & South Korea (NCT01753076)
- 31 Dec 2013 Phase-II clinical trials in Amyotrophic lateral sclerosis in USA, Japan & South Korea (IV)